Navigation Links
GenSpera G-202 data in journal

GenSpera, Inc. (OTCBB:GNSZ) announced that a study titled, "Engineering the Plant Product Thapsigargin into a PSMA-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy," was published in the journal, Science Translational Medicine, on June 27, 2012 ( The manuscript documents the extensive pre-clinical data and rationale for the development of G-202 as a potential treatment for a variety of solid tumors in human patients.

The paper also validated the enzyme, PSMA, as an appropriate molecular target for G-202. PSMA is expressed by both prostate cancer cells and endothelial (vascular) cells in a variety of cancers, but not by most normal tissues. Finally, the paper showed G-202 toxicity to be low in animal models. Based on these results, the researchers concluded that the G-202 cytotoxin and prodrug delivery platform produced sufficient therapeutic results to support advancing G-202 to human clinical trials.

"This publication marks the culmination of 40 years of collaborative, interdisciplinary research," said Sren Brgger Christensen, PhD, study author, Professor at the University of Copenhagen and a member of GenSpera's Scientific Advisory Board. "We began studying the medicinal properties of the plant, Thapsia garganica, in the 1970's. Our group was the first to isolate the active ingredient, thapsigargin, elucidate its chemical structure and demonstrate that it kills tumor cells by blocking a specific intracellular calcium pump. Thapsigargin kills cells independently of their rate of cell division, which we believe can make it more effective than standard chemotherapeutic agents in treating a wide variety of human tumors."

"This paper represents a rare 'brain-to-bench-to-bedside' translational story," said John Isaacs, PhD, study author, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and a member of GenSpera's Scientific Advisory Board. "We engineered a 'molecular grenade' to deliver the superior anti-cancer activity of thapsigargin directly to the tumor, thereby unleashing its therapeutic potential at the cancer site. We are encouraged by our remarkable results in multiple human cancer models in mice and look forward to the outcome of the ongoing human clinical study."


Contact: Deanne Eagle
Planet Communications

Related medicine news :

1. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
2. Anti-cocaine vaccine described in Human Gene Therapy Journal
3. New England Journal of Medicine hails new skin cancer drug as greatest advance yet
4. Elsevier, SVS announce 2013 launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
5. NAMS journal Menopause reflects on the WHI 10 years later
6. Reactions to HIV drug have autoimmune cause, reports AIDS journal
7. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
8. Journals and pharma collaborate on new recommendations
9. Model for breast cancer rehab featured in supplement to ACS journal, Cancer
Post Your Comments:
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment ... video interviews with some of the staff members at their recovery center. The videos ... as well as some of the things that make their recovery program so unique. ...
(Date:11/24/2015)... PALMYRA, Wis (PRWEB) , ... November 24, 2015 ... ... Process scholarship award at Cleveland University-Kansas City (CU-KC), in Overland Park, ... scholarship from Chiropractor and University President Carl S. Cleveland III on October 16. ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Fragrance by Marcelle, a cosmetic invention which offers a ... & Fragrance Manufacturing Market in the US is worth $3 billion annually," says ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological Society ... Chicago on Nov-29 th through Dec-4 ...  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th , ... present its revolutionary whole body CZT digital SPECT/CT solution at the ...
Breaking Medicine Technology: